FAQ

lymphokine-activated killer cell therapy

Known as: LAK cell therapy, cell therapy, lymphokine-activated killer, therapy, lymphokine-activated killer cell 
The use of lymphokine-activated killer cells in the treatment of any disease or disorder.

Topic mentions per year

Topic mentions per year

1986-2011
024619862011

Related topics

Related topics

2 relations
Lymphokine-Activated Killer Cellsinterleukin-2/lymphokine-activated killer cells

Related mentions per year

Related mentions per year

1974-2018
197019801990200020102020
lymphokine-activated killer cell therapy
Lymphokine-Activated Killer Cells
interleukin-2/lymphokine-activated killer cells

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Lymphokine-activated killer cell therapy combined with high-dose glucocorticoid showed clinical efficacy towards advanced lung carcinoma.
We describe the case of a patient with terminal adenocarcinoma of the lung with no response to lymphokine-activated killer (LAK… (More)
  • figure 1
Is this relevant?
2009
2009
Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma.
Despite recent advances, median survival for patients with resectable glioblastoma multiforme (GBM) is only 12 to 15 months. We… (More)
  • table 2
  • table 1
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
1997
1997
Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients.
Lymphoreticular malignancies, collectively called posttransplant lymphoproliferative disorders (PTLD), eventually develop in 2-5… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
Is this relevant?
1997
1997
Autologous lymphokine-activated killer cell therapy of lymphoproliferative disorders arising in organ transplant recipients.
B CELL lymphomas which often contain the EpsteinBarr virus (EBY) make up the preponderance of tumors that collectively have been… (More)
Is this relevant?
1991
1991
Interleukin-2 lymphokine-activated killer cell therapy of non-Hodgkin's lymphoma and Hodgkin's disease.
We conducted a phase II study utilizing interleukin-2 (IL-2) with lymphokine-activated killer (LAK) cells as therapy for non… (More)
Is this relevant?
1990
1990
Acalculus lymphoeosinophilic cholecystitis associated with interleukin-2 and lymphokine-activated killer cell therapy.
A case of unusual cholecystitis that developed on completion of interleukin-2 and lymphokine-activated killer cell therapy is… (More)
Is this relevant?
1990
1990
Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells.
Fifty patients with advanced melanoma received high-dose bolus and continuous infusion interleukin-2 (IL-2) with lymphokine… (More)
Is this relevant?
1990
1990
Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
Several groups have described the efficacy of interleukin 2 (IL-2) plus lymphokine-activated killer (LAK) cells in the treatment… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
1987
1987
In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy.
Patients with advanced metastatic cancer were given combined autologous lymphokine activated killer (LAK) cell and recombinant… (More)
Is this relevant?
Highly Cited
1986
Highly Cited
1986
A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.
The adoptive transfer of tumor-infiltrating lymphocytes (TIL) expanded in interleukin-2 (IL-2) to mice bearing micrometastases… (More)
Is this relevant?